Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Lung Cancer—Non-Small Cell Metastatic

Type: Poster Session

Time: Sunday June 2, 8:00 AM to 11:00 AM

Location: Hall A

Session: Lung Cancer—Non-Small Cell Metastatic

Type: Poster Discussion Session

Time: Sunday June 2, 4:30 PM to 6:00 PM

Location: Hall D1

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).

Metastatic Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Metastatic

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Discussion Session (Board #335)

J Clin Oncol 37, 2019 (suppl; abstr 9012)

Author(s): Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Tony S. K. Mok, Howard West, Makoto Nishio, Vassiliki Papadimitrakopoulou, Francisco J Orlandi, Daniil Stroyakovskiy, Christian A. Thomas, Naoyuki Nogami, Fabrice Barlesi, Anthony Lee, Geetha Shankar, Wei Yu, Marcus Ballinger, Ilze Bara, Alan Sandler, Martin Reck; AdventHealth Cancer Institute, Orlando, FL; Rocky Mountain Cancer Centers, Denver, CO; Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy; Prince of Wales Hospital, Hong Kong, China; Swedish Cancer Institute, Seattle, WA; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Instituto Nacional del Torax, Santiago, Chile; Moscow City Oncology Hospital, Moscow, Russian Federation; New England Cancer Specialists, Scarborough, ME; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Genentech, Inc., South San Francisco, CA; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany

Abstract Disclosures


Background: Atezolizumab (atezo) + bevacizumab (bev) + chemo (carboplatin + paclitaxel [CP]; ABCP) showed improved PFS and OS vs bev + CP (BCP) in pts with chemo-naive NSCLC (IMpower150). Benefit with ABCP vs BCP extended to key subgroups, including pts with baseline (BL) liver mets, which is a poor prognostic factor in metastatic NSCLC. Similar outcomes were not seen with atezo + chemo (IMpower150 [atezo + CP; ACP]; IMpower130; IMpower132), suggesting that the addition of bev to atezo + chemo is important for conferring clinical benefit in these pts. Here we further explore characteristics and responses of pts with BL liver mets in IMpower150. Methods: 1202 ITT pts were randomized 1:1:1 to receive ABCP, ACP or BCP. Doses were: A, 1200 mg; B, 15 mg/kg; C, AUC 6 mg/mL/min; P, 200 mg/m2. Coprimary endpoints were OS and investigator-assessed PFS in ITT–wild-type pts. Exploratory analyses included efficacy and safety in pts with liver mets. Results: The data capture ≥ 20-mo follow-up in ITT pts (data cutoff: Jan 22, 2018). 162 pts had BL liver mets (ABCP, n = 52; ACP; n = 53; BCP, n = 57), with a median of 3 metastatic sites and median BL tumor SLD of 109 mm (range, 10-249). BL characteristics in these pts were generally balanced across study arms. PFS and OS were improved with ABCP vs BCP (Table). Gr 3-4 treatment-related AEs occurred in 52.1%, 36.5% and 54.5% of pts with liver mets in the ABCP, ACP and BCP arms, respectively. Conclusions: ABCP reduced the risk of death in pts with liver mets by 48% vs BCP and may represent an important new treatment option for this population. Clinical trial information: NCT02366143

of liver mets
mPFS, mo
HR (95% CI)
ACP vs
n = 52n = 53n = 57(0.26, 0.62)(0.55, 1.21)
n = 348n = 349n = 343(0.52, 0.73)(0.77, 1.06)
mOS, moHR (95% CI)
n = 52n = 53n = 57(0.33, 0.82)(0.57, 1.32)
n = 348n = 349n = 343(0.66, 1.02)(0.68, 1.04)
ORR, %aDifference (95% CI), %
n = 51n = 52n = 56(-0.75, 40.18)(-33.65, 5.35)
n = 346n = 349n = 337(8.03, 23.4)(-5.03, 10.29)
mDOR, moHR (95% CI)
n = 31n = 15n = 23(0.21, 0.73)(0.29, 1.23)
n = 193n = 149n = 138(0.33, 0.55)(0.40, 0.69)

a Pts with measurable disease at BL

Other Abstracts in this Sub-Category:


1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer


2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer


3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer